Physician profile
William Mcallister
NPI 1740224278
$2,532.20
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $397 · 2021: $473 · 2022: $229 · 2023: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $615.16 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $386.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $368.20 | 2019-2023 | Spravato |
| Axsome Therapeutics, INC. | $244.42 | 2023 | Auvelity |
| Lundbeck LLC | $140.80 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $139.86 | 2019-2021 | |
| Alkermes, INC. | $134.32 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $134.06 | 2019-2022 | |
| Abbvie INC. | $72.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.85 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $47.81 | 2019-2020 | |
| Indivior INC. | $44.22 | 2022 | |
| Neurocrine Biosciences, INC. | $38.83 | 2019-2020 | |
| Allergan, INC. | $28.57 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.48 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $15.11 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.41 | 2019 | |
| Shire North American Group INC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcallister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.